WST · West Pharmaceutical Services, I
$358.41
-4.75% last session
End-of-day data · updated 2026-07-24
Market cap
$25B
Enterprise value
$25B
Trailing P/E
47.5
Forward P/E
37.0
Dividend yield
0.0%
Beta
1.16
Avg volume
1M
Employees
11K
2D change
-0.82%
5D change
-0.77%
10D change
-0.61%
30D change
4.43%
60D change
12.34%
MTD change
-2.61%
YTD change
29.42%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — WST
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-13
Latest call per bank · past 12 months
Morgan Stanley
Equal-Weight$365
+1.8% vs priceBarclays
Overweight$400
+11.6% vs priceUBS
Buy$355
-1.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-13 | BNP Paribas | Initiates | Outperform | $0.00 → $447 |
| 2026-07-09 | Morgan Stanley | Maintains | Equal-Weight | $325 → $365 |
| 2026-07-06 | Evercore ISI Group | Maintains | Outperform | $390 → $410 |
| 2026-07-02 | Keybanc | Maintains | Overweight | $350 → $390 |
| 2026-06-09 | Barclays | Upgrade | Equal-Weight → Overweight | $310 → $400 |
| 2026-06-02 | Stephens & Co. | Reiterates | Overweight | $360 |
| 2026-05-29 | Morgan Stanley | Maintains | Equal-Weight | $315 → $325 |
| 2026-04-27 | Barclays | Maintains | Equal-Weight | $275 → $310 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-24
- RSI (14): RSI is 42 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 1.1% above the 50-day MA ($334.94).
- Price vs 200-day MA: Trading 19.7% above the 200-day MA ($282.86).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-2.94) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($230.78) and high ($365.74).
WST Price Chart
Loading chart for WST…
Fundamentals
About West Pharmaceutical Services, I
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
More in Medical Instruments & Supplies
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.